Preclinical and clinical observations, though limited, solidify the rationale for the clinical development of ICI for the treatment of HER2-positive breast carcinoma, and emphasize the need for more detailed research into the development of immunotherapeutic modules, especially in combination with HER2-targeted therapies. Here, ERBB2 is linked to breast carcinoma.